Scott Gottlieb is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. Dr. Gottlieb’s work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety. Dr. Gottlieb is an aggressive advocate for advancing the health of patients, promoting healthcare access, and driving innovation. Under his leadership, the FDA implemented new reforms to standardize drug reviews and make historic improvements of post market data collection and the use of real-world evidence.

Fortune Magazine recognized him as one of the “World’s 50 Greatest Leaders” in 2018 and again in 2019. In 2018, 2019 and then again in 2020, Modern Healthcare named Dr. Gottlieb the “Most Influential Physician Executive and Leaders” in its annual survey of 50 physician executives, and Time magazine named him one of its “50 People Transforming Healthcare in 2018.” In addition to Tempus, Dr. Gottlieb also serves on the boards of Pfizer Inc. and Illumina, Inc., is a resident fellow at the American Enterprise Institute and a partner at the venture capital firm New Enterprise Associates.